Researchers in Japan have identified a protein that might help predict who will respond well to treatment for classical Hodgkin lymphoma, and who might need more intensive treatment.
The protein is called ‘soluble interleukin-2 receptor’ or sIL-2R. It is made by lymphocytes and other immune cells and can be measured using a blood test.
The study found that people who had a high level of sIL-2R in their blood when they were diagnosed with classical Hodgkin lymphoma responded less well to ABVD treatment than people with lower levels of sIL-2R.
This was a very small study and more research is needed into the role of sIL-2R. If the results of this study are confirmed, measuring sIL-2R at diagnosis might help specialists identify people who need more intensive treatment strategies for classical Hodgkin lymphoma.
20 November 2019